Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

BACKGROUND: Serotonin (5HT), a naturally occurring vasoactive substance, is released from platelets into plasma under various pathological conditions. Recently, anticancer drugs that act by selectively disrupting tumour blood flow have been found to increase plasma 5HT concentrations in mice. Two su...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kestell, P, Zhao, L, Jameson, M, Stratford, MR, Folkes, L, Baguley, B
Format:	Journal article
Język:	English
Wydane:	2001

Podobne zapisy

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
od: Stratford, MR, i wsp.
Wydane: (2011)

Rat Tumor Response to the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Plasma 5-Hydroxyindoleacetic Acid Levels, and Tumor Necrosis
od: Lesley D. McPhail, i wsp.
Wydane: (2006-03-01)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.
od: Stratford, MR, i wsp.
Wydane: (2012)

Serum 5-Hydroxyindoleacetic Acid and Ratio of 5-Hydroxyindoleacetic Acid to Serotonin as Metabolomics Indicators for Acute Oxidative Stress and Inflammation in Vancomycin-Associated Acute Kidney Injury
od: Hyun-Seung Lee, i wsp.
Wydane: (2021-06-01)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
od: Stratford, MR, i wsp.
Wydane: (2012)

Use of Arsenic Trioxide as an Antivascular and Thermosensitizing Agent in Solid Tumors
od: Robert J. Griffin, i wsp.
Wydane: (2000-01-01)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection
od: Stratford, M, i wsp.
Wydane: (2011)

5-Hydroxyindoleacetic acid as a biomarker for revealing perforation in acute appendicitis
od: Arash Mohammadi Tofigh, i wsp.
Wydane: (2024-10-01)

Tryptophan Challenge in Healthy Controls and People with Schizophrenia: Acute Effects on Plasma Levels of Kynurenine, Kynurenic Acid and 5-Hydroxyindoleacetic Acid
od: Korrapati V. Sathyasaikumar, i wsp.
Wydane: (2022-08-01)

Impact of plasma 5-hydroxyindoleacetic acid, a serotonin metabolite, on clinical outcome in septic shock, and its effect on vascular permeability
od: Takeshi Tanaka, i wsp.
Wydane: (2021-07-01)

Autoimmune Pancreatitis Associated with High Levels of Chromogranin A, Serotonin and 5-Hydroxyindoleacetic Acid
od: Elisabetta Nobili, i wsp.
Wydane: (2008-01-01)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation
od: Stratford, M, i wsp.
Wydane: (2012)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
od: Ilias Zampros, i wsp.
Wydane: (2012-01-01)

Zinc-Substituted Pheophorbide A Is a Safe and Efficient Antivascular Photodynamic Agent
od: Milena J. Szafraniec, i wsp.
Wydane: (2022-02-01)

Promising novel treatment against keloids: Antivascular endothelial growth factor agents
od: Bahareh Abtahi-Naeini, i wsp.
Wydane: (2019-01-01)

Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity.
od: Hoskin, P, i wsp.
Wydane: (2000)

Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels
od: Husnain Abbas Shah, i wsp.
Wydane: (2022-04-01)

Influence of plasma glutathione levels on radiation mucositis.
od: Wardman, P, i wsp.
Wydane: (2001)

Bypass of Tumor Drug Resistance by Antivascular Therapy
od: Dina Preise, i wsp.
Wydane: (2003-11-01)

5-Hydroxyindoleacetic acid, a new ligand for GPR35, plays an important role in inflammatory disease
od: Yang Zhisheng, i wsp.
Wydane: (2022-12-01)

The correlation between urinary 5-hydroxyindoleacetic acid and sperm quality in infertile men and rotating shift workers
od: Pariente José A, i wsp.
Wydane: (2010-11-01)

Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels
od: Christopher Adams, i wsp.
Wydane: (2023-01-01)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
od: Kumar Anshuman, i wsp.
Wydane: (2019-01-01)

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
od: Xiaocong Ma, i wsp.
Wydane: (2023-04-01)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
od: Ajay Indur Dudani, i wsp.
Wydane: (2019-01-01)

Multi-omic Profiling Reveals that Intra-abdominal-Hypertension-Induced Intestinal Damage Can Be Prevented by Microbiome and Metabolic Modulations with 5-Hydroxyindoleacetic Acid as a Diagnostic Marker
od: Fang Li, i wsp.
Wydane: (2022-06-01)

Increase of Urinary 5-Hydroxyindoleacetic Acid Excretion but Not Serum Chromogranin a Following Over-The-Counter 5-Hydroxytryptophan Intake
od: Tisha Joy, i wsp.
Wydane: (2008-01-01)

5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy.
od: Folkes, L, i wsp.
Wydane: (2002)

Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer
od: Chueh-Yi Huang, i wsp.
Wydane: (2016-06-01)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
od: Merryl R Lobo, i wsp.
Wydane: (2015-01-01)

Assessment of Serotonin Metabolite 5-hydroxyindoleacetic Acid Levels in Urine Sample for Diagnosis and Treatment Efficacy in Children with Dysfunctional Voiding and Their Interaction with Biofeedback Therapy
od: Bahadır Topuz, i wsp.
Wydane: (2018-12-01)

Plasma superoxide dismutase-1 as a surrogate marker of vivax malaria severity.
od: Bruno B Andrade, i wsp.
Wydane: (2010-04-01)

Acute renal failure after intravitreal antivascular endothelial growth factor therapy
od: Yu-Fang Huang, i wsp.
Wydane: (2017-06-01)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
od: Tranos P, i wsp.
Wydane: (2013-06-01)

Intravitreal antivascular endothelial growth factors for retinopathy of prematurity in Ibadan: Method of administration
od: Yewande Olubunmi Babalola, i wsp.
Wydane: (2020-01-01)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
od: Yukio Sassa, i wsp.
Wydane: (2010-04-01)

Surrogate markers in HIV disease.
od: Peto, T
Wydane: (1996)

Surrogates Markers of Insulin Resistance
od: Ekhlas Khalid Hameed, i wsp.
Wydane: (2022-05-01)

Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings
od: Ashwini Shete, i wsp.
Wydane: (2020-07-01)

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.
od: Folkes, L, i wsp.
Wydane: (2007)